CVS Health Corp vs General Dynamics Corporation — how do they compare? CVS Health Corp trades at $87.25 (market cap $112.29B), while General Dynamics Corporation trades at $331.24 (market cap $89.26B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and General Dynamics Corporation for 85 Days on average.
| CVS | GD | |
|---|---|---|
Market Cap | $112.29B | $89.26B |
Volume | 7,763,676 | 1,496,273 |
Sector | Health | Industrials |
52-Week High | $110.60 | $395.97 |
52-Week Low | $70.08 | $312.53 |
Typical Hold Time | 83 Days | 85 Days |
Enterprise Value | $174.64B | $94.40B |
Dividend Yield | 3.03% | 1.93% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.
CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.
General Dynamics (GD) trades at $331.77, up 1.57% today, with a bearish technical signal but strong fundamental performance. Recent quarters have consistently beaten EPS estimates, with Q3 2026 expected at $4.14. Revenue grew to $52.55B in 2025, and net income margin improved to 8.18%. Analyst consensus is bullish with a $420.57 price target, supported by defense budget tailwinds and dividend stability.
The outlook remains positive due to robust Pentagon spending and contract visibility, though technical weakness near support at $320 poses short-term risk. Long-term growth is underpinned by submarine and vehicle demand, but investors face volatility from defense budget cycles and geopolitical uncertainties. The stock offers value with a P/E of 20.12 and a sustainable dividend.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →